We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs
News

Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs

Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs
News

Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Metabolon, Inc. has announced a new study has been published which seeks to better understand the toxicological uncertainties of fenofibrate. Co-authored by Metabolon and Mitsubishi Tanabe Pharma, “Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats” appears in Toxicologic Pathology.

“Complete mechanistic understanding of the full effects of fibrate action is still quite limited,” explained Naohisa Tsutsui, one of the authors of the paper from Mitsubishi Tanabe Pharma.

“In this study, we applied global biochemical profiling as a means to gain further insight into the molecular mechanisms of fenofibrate and better understand its pharmacology and toxicology. This technology offered us a valuable tool in the process of new hypothesis generation.”

A widely-used drug, fenofibrate belongs to the fibrate class of drugs that have been used to treat patients with a variety of metabolic disorders and is often a preferred therapy in combination with statins to treat people with dyslipidemia. While fenofibrate is considered safe in humans, it is known to have toxicological effect in rodents. This study was an investigation of the efficacy and toxicological effects of this class of drugs in rodents.

“The toxicological concerns surrounding this class of drugs and a true understanding of their mechanisms has long been an area of intensive research,” said Lining Guo, senior director and head of commercial operations with Metabolon. “This study found significant biochemical effects of fenofibrate treatment in rodents that demonstrates the power of a non-targeted metabolomics approach.”
Advertisement